Loading...
XNYS
NVS
Market cap210bUSD
Mar 31, Last price  
111.48USD
1D
-0.97%
1Q
14.56%
Jan 2017
70.88%
Name

Novartis AG

Chart & Performance

D1W1MN
XNYS:NVS chart
No data to show
P/E
17.72
P/S
4.09
EPS
6.29
Div Yield, %
6.78%
Shrs. gr., 5y
-2.66%
Rev. gr., 5y
1.22%
Revenues
51.72b
+10.85%
32,526,000,00036,749,000,00038,947,000,00042,584,000,00045,103,000,00051,561,000,00059,375,000,00057,561,000,00058,831,000,00053,634,000,00050,387,000,00049,436,000,00050,135,000,00053,166,000,00048,677,000,00049,898,000,00052,877,000,00051,828,000,00046,660,000,00051,722,000,000
Net income
11.94b
-19.59%
6,130,000,0007,175,000,00011,946,000,0008,195,000,0008,400,000,0009,794,000,0009,113,000,0009,505,000,0009,175,000,00010,210,000,00017,783,000,0006,712,000,0007,703,000,00012,611,000,0007,147,000,0008,072,000,00024,021,000,0006,955,000,00014,850,000,00011,941,000,000
CFO
17.62b
+21.86%
8,080,000,0008,710,000,0009,210,000,0009,769,000,00012,191,000,00014,067,000,00014,309,000,00014,194,000,00013,174,000,00013,897,000,00011,897,000,00011,475,000,00012,621,000,00014,272,000,00013,625,000,00013,650,000,00015,071,000,00014,236,000,00014,458,000,00017,619,000,000
Dividend
Sep 24, 20243.77721 USD/sh
Earnings
Apr 21, 2025

Profile

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
URL
https://www.novartis.com/
IPO date
May 07, 2001
Employees
103,000
Domiciled in
CH
Incorporated in
CH

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
51,722,000
10.85%
46,660,000
-9.97%
51,828,000
-1.98%
Cost of revenue
22,849,000
23,843,000
25,482,000
Unusual Expense (Income)
NOPBT
28,873,000
22,817,000
26,346,000
NOPBT Margin
55.82%
48.90%
50.83%
Operating Taxes
1,701,000
551,000
1,416,000
Tax Rate
5.89%
2.41%
5.37%
NOPAT
27,172,000
22,266,000
24,930,000
Net income
11,941,000
-19.59%
14,850,000
113.52%
6,955,000
-71.05%
Dividends
(7,624,000)
(7,255,000)
(7,506,000)
Dividend yield
4.24%
4.09%
4.09%
Proceeds from repurchase of equity
(8,331,000)
(8,719,000)
(10,552,000)
BB yield
4.63%
4.91%
5.75%
Debt
Debt current
8,324,000
6,314,000
6,182,000
Long-term debt
24,737,000
21,862,000
23,571,000
Deferred revenue
Other long-term liabilities
4,075,000
4,523,000
4,906,000
Net debt
18,582,000
12,387,000
8,269,000
Cash flow
Cash from operating activities
17,619,000
14,458,000
14,236,000
CAPEX
(1,366,000)
(2,753,000)
(2,671,000)
Cash from investing activities
(7,513,000)
5,596,000
1,468,000
Cash from financing activities
(11,742,000)
(14,278,000)
(20,562,000)
FCF
27,223,000
23,537,000
25,841,000
Balance
Cash
13,351,000
13,962,000
18,930,000
Long term investments
1,128,000
1,827,000
2,554,000
Excess cash
11,892,900
13,456,000
18,892,600
Stockholders' equity
44,179,000
46,791,000
123,055,000
Invested Capital
67,566,100
64,165,000
70,867,400
ROIC
41.25%
32.98%
34.48%
ROCE
35.26%
28.57%
28.50%
EV
Common stock shares outstanding
2,027,000
2,092,000
2,197,000
Price
88.70
4.51%
84.87
1.53%
83.59
4.12%
Market cap
179,794,900
1.27%
177,548,040
-3.32%
183,647,221
1.22%
EV
198,456,900
190,018,040
191,997,221
EBITDA
34,942,000
31,094,000
33,527,000
EV/EBITDA
5.68
6.11
5.73
Interest
1,006,000
855,000
837,000
Interest/NOPBT
3.48%
3.75%
3.18%